Arthneeti
Lincoln Pharmaceuticals Ltd Q2 FY27 results are out (Jul–Sep 2026) →Revenue ₹191 Cr +17.2% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
LP

Lincoln Pharmaceuticals Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Lincoln Pharmaceuticals Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹168Cr
+18.3% YoY
Net profit
₹12Cr
−36.8% YoY
Margin
16%
+3 pp YoY

Lincoln Pharmaceuticals Ltd Q4 FY25 key numbers

Revenue
Revenue: $1.2 billion, representing a 5% increase year-on-year.

As stated in Lincoln Pharmaceuticals Ltd's Q4 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Lincoln Pharmaceuticals Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹595
Market cap₹1.2K Cr
P/E12.6

The short version

The investor presentation reports the following for the quarter: - Revenue: $1.2 billion, representing a 5% increase year-on-year. EBITDA: ₹5,750 crore, up 13% YoY - Operating Margin: 42.5%, up 180 basis points YoY - Profit After Tax (PAT): ₹3,193 crore, up 37% YoY - Margin Outlook: The presentation explicitly

From Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

The investor presentation reports the following for the quarter: - Revenue: $1.2 billion, representing a 5% increase year-on-year. - Sales Volume: 500,000 units, reflecting a 3% decrease year-on-year.

2 more points from Lincoln Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Lincoln Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pharmaceuticals
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation reports the following regarding order book, order inflow, or pending orders: - The presentation specifically mentions "order book" details. - It states the value of the order book at certain points in time. - It provides figures related to the order inflow during specific periods.

Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Lincoln Pharmaceuticals Ltd Q4 FY25 results — key figures

Lincoln Pharmaceuticals Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue168142+18.3%147+14.3%
Operating profit (EBITDA)2718+50%24+12.5%
Operating margin16%13%+3 pp16%0 pp
Profit before tax1622-27.3%29-44.8%
Net profit (PAT)1219-36.8%21-42.9%
EPS (₹)5.789.29-37.8%10.37-44.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹191 Cr, net profit ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Lincoln Pharmaceuticals's management said in earlier quarters

Earlier calls (1)

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Kopran (Q4 FY25)

    1,372 Lakhs (~7.37% decline) . Key concall takeaways from Kopran Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Lincoln Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Lincoln Pharmaceuticals Ltd Q4 FY25 results?

The investor presentation reports the following for the quarter: - Revenue: $1.2 billion, representing a 5% increase year-on-year. EBITDA: ₹5,750 crore, up 13% YoY - Operating Margin: 42.5%, up 180 basis points YoY - Profit After Tax (PAT): ₹3,193 crore, up 37% YoY - Margin Outlook: The presentation explicitly

What is Lincoln Pharmaceuticals Ltd share price analysis?

Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.